BioWorld data methodology

Clinical data

Phase 1 - 2025	Phase II - 2025	Phase III - 2025	Regulatory - 2025
Phase 1 - 2024	Phase II - 2024	Phase III - 2024	Regulatory - 2024
Phase 1 - 2023	Phase II - 2023	Phase III - 2023	Regulatory - 2023
Phase 1 - 2022	Phase II - 2022	Phase III - 2022	Regulatory - 2022
Phase I - 2021	Phase II - 2021	Phase III - 2021	Regulatory - 2021
Phase I - 2020	Phase II - 2020	Phase III - 2020	Regulatory - 2020

Products approved

2025	2024	2023	2022	2021
2020	2019	2018	2017	2016
1982-2015

Drugs on deck

2025

Market capitalization

Snapshots market capitalization

Grants

2025

2024

2023

2022

2021

2020

IPOs

2025	2024	2023	2022	2021	2020
2019	2018	2017	2016	2015	2014
2013	2012	2011	2010	2009	2008
2007	2006	2005	2004	2003	2002
2001	2000	1999

Follow-on offerings

2025	2024	2023	2022	2021	2020
2019	2018	2017	2016	2015	2014
2013	2012	2011	2010	2009	2008
2007	2006	2005	2004	2003	2002
2001	2000

Public/other financings

2025	2024	2023	2022	2021	2020
2019	2018	2017	2016	2015	2014
2013	2012	2011	2010	2009	2008
2007	2006	2005	2004	2003	2002
2001	2000	1999

Venture capital financings

2025	2024	2023	2022	2021	2020
2019	2018	2017	2016	2015	2014
2013	2012	2011	2010	2009	2008
2007	2006	2005	2004	2003	2002
2001	2000	1999

Biopharma company deals

2025	2024	2023	2022	2021	2020
2019	2018	2017	2016	2015	2014
2013	2012	2011	2010	2009	2008
2007	2006	2005	2004	2003	2002
2001	2000	1999

Biopharma/nonprofit deals

2025

2024

2023

2022

2021

2020

Mergers and acquisitions

2025	2024	2023	2022	2021	2020
2019	2018	2017	2016	2015	2014
2013	2012	2011	2010	2009	2008
2007	2006	2005	2004	2003	2002
2001	2000	1999